The Pulse of Private Equity – 2/23/2026

Why It Matters

The unprecedented growth and mega‑deal signal that private equity sees durable cash flow and consolidation opportunities in healthcare devices, reshaping industry dynamics and valuation benchmarks.

Key Takeaways

• Healthcare devices deals grew 270% YoY in 2025
• Hologic LBO valued at $18.3 billion, largest this year
• Deal financed with senior debt, mezzanine, and equity
• PE firms target fragmented medical‑device markets for roll‑ups

Pulse Analysis

Private equity investment in healthcare has accelerated, with the devices and supplies segment outpacing all other sub‑sectors in 2025. The segment posted a 270 % year‑over‑year increase in deal value, reflecting heightened demand for diagnostic equipment, minimally invasive tools and home‑care technologies. Investors are drawn by stable reimbursement models, aging demographics and the ability to scale innovative product portfolios through roll‑up strategies. Moreover, the pandemic accelerated telehealth adoption, prompting hospitals to upgrade imaging and point‑of‑care devices, further inflating transaction sizes. Private equity firms are also leveraging data‑analytics platforms to identify under‑penetrated product lines, creating synergies across portfolio companies.

The catalyst for this surge was Hologic’s $18.3 billion leveraged buyout announced in the fourth quarter, the largest healthcare‑focused LBO of the year. The transaction, financed through a mix of senior debt, mezzanine capital and equity contributions, underscores lenders’ confidence in the company’s cash‑flow resilience and growth pipeline in women's health and diagnostics. By taking Hologic private, the sponsor aims to accelerate R&D, streamline operations and position the business for a strategic exit within five to seven years. The deal also signals a broader trend of consolidating diagnostic capabilities under single ownership, enhancing bargaining power with insurers.

Analysts expect the momentum to continue as other niche medical‑device firms become attractive targets for roll‑up platforms seeking to consolidate fragmented markets. However, the steep valuation multiples and heightened debt levels raise concerns about credit risk if reimbursement policies tighten or innovation cycles slow. Regulators are watching closely, as increased concentration could affect pricing dynamics and patient access, prompting potential antitrust reviews. Firms that can demonstrate operational efficiencies and clear pathways to revenue expansion will likely secure the most favorable financing terms and drive the next wave of private‑equity value creation in healthcare.